Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 2079-2090

  Moeller, Ines ^a,b   Spagnoli, Giulio C ^c   Finke, Jürgen ^a   Veelken, Hendrik ^a   Houet, Leonora ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Dendritic cells; Endocytosis; Fc receptors; Tumor immunity

Indexed keywords

BORTEZOMIB; CD4 ANTIGEN; CD8 ANTIGEN; CELL RECEPTOR; FC RECEPTOR; HEAT SHOCK PROTEIN 90; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELL SURFACE; CELL TYPE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; GAMMA IRRADIATION; HUMAN; HUMAN CELL; INTERNALIZATION; MULTIPLE MYELOMA; MYELOMA CELL; OPSONIZATION; PHAGOCYTOSIS; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; T LYMPHOCYTE ACTIVATION;

ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; GAMMA RAYS; HUMANS; MELANOMA; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PINOCYTOSIS; PYRAZINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84871008234     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1272-y     Document Type: Article

References (27)

1. Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684-693
2. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K et al (2009) Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 15:1343-1352
3. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y et al (2007) MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGEpositive cell lines. Cancer Res 67:9954-9962
4. Laduron S, Deplus R, Zhou S, Kholmanskikh O, Godelaine D et al (2004) MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 32:4340-4350
5. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S et al (2006) MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 103:11160-11165
6. Marcar L, Maclaine NJ, Hupp TR, Meek DW (2010) Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 70:10362-10370
7. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA et al (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105:1650-1655
8. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P (1998) Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer 77:538-542
9. Brichard VG, Lejeune D (2007) GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development. Vaccine 25(Suppl 2):B61-B71
10. Schnurr M, Chen Q, Shin A, Chen W, Toy T et al (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105:2465-2472
11. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV (2002) Antitumor monoclonal antibodies enhance cross-presentation of Cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125-133
12. Jeannin P, Jaillon S, Delneste Y (2008) Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 20:530-537
13. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S et al (2007) Bortezomib enhances dendritic cell (DC)-mediatedinduction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications. Blood 109:4839-4845
14. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L et al (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135-3142
15. Thomas-Kaskel AK, Portugal TG, Herchenbach D, Houet LV, Finke HJ (2007) Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes. Acta Haematol pp 226-235
16. van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C et al (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51-64
17. Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J et al (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4? T-cell epitopes on the tumor antigen MAGE-3. Blood 101:1038-1044
18. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F et al (2007) Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109:1103-1112
19. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F et al (2007) Immunization with a recombinant MAGE-A3 protein after highdose therapy for myeloma. J Immunother 30:847-854
20. Lambert SL, Okada CY, Levy R (2004) TCR vaccines against a murine T cell lymphoma: A primary role for antibodies of the IgG2c class in tumor protection. J Immunol 172:929-936
21. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34-47
22. Iida S, Kuni-Kamochi RMK, Misaka H, Inoue M et al (2009) Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 9:58
23. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG et al (2006) The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 66:1261-1264
24. Basu S, Binder RJ, Ramalingam T, Srivastava PK (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303-313
25. Liu B, Dai J, Zheng H, Stoilova D, Sun S et al (2003) Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci USA 100:15824-15829
26. Dai J, Liu B, Caudill MM, Zheng H, Qiao Y et al (2003) Cell surface expression of heat shock protein gp96 enhances crosspresentation of cellular antigens and the generation of tumorspecific T cell memory. Cancer Immun 3:1
27. di Pietro A, Tosti G, Ferrucci PF, Testori A (2009) Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get. Hum Vaccin 5:727-737